Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote

A panel of FDA advisers is set to vote on whether to recommend the approval of Grail's Galleri blood test, which claims to detect up to 50 types of cancer from a single blood sample. If approved, this could revolutionize early cancer detection, potentially catching cancers at a much earlier stage when treatment is more effective. The decision holds significant implications for public health, offering a non-invasive alternative to traditional cancer screenings and possibly reducing mortality rates associated with late-stage cancer diagnoses.